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Introduction: We previously demonstrated in both a longitudinal study and in meta- 
analysis (pooled relative- risk RR, 2.45) that all- cause mortality is significantly higher 
in people with diabetes foot ulceration (DFU) than with those without a foot ulcer. In 
this prospective study, we looked at the factors linked to mortality after presentation 
to podiatry with DFU.
Methods: Ninety- eight individuals recruited consecutively from the Salford Royal 
Hospital Multidisciplinary Foot Clinic in Spring 2016 were followed up for up to 
48 months. Data concerning health outcomes were extracted from the electronic pa-
tient record (EPR).
Results: Seventeen people (17) had type 1 diabetes mellitus, and 81 had type 2 diabe-
tes mellitus. Thirty- one were women. The mean age (range) was 63.6 (28– 90) years 
with maximum diabetes duration 45 years. Mean HbA1c was 72 (95% CI: 67– 77) 
mmol/mol; 97% had neuropathy (International Working Group on the Diabetic Foot 
(IWGDF) monofilament); 62% had vascular insufficiency (Doppler studies); 69% of 
ulcers were forefoot, and 23% of ulcers were hind foot in location.
Forty of 98 (40%) patients died in follow- up with 27% of death certificates including 
sepsis (not foot- related) and 35% renal failure as cause of death. Multivariate regres-
sion analysis indicated a 6.3 (95% CI: 3.9– 8.1) fold increased risk of death with hind 
foot ulcer, independent of age/BMI/gender/HbA1c/eGFR/total cholesterol level.
Conclusion: This prospective study has indicated a very high long- term mortality 
rate in individuals with DFU, greater for those with a hind foot ulcer and shown a 
close relation between risk of sepsis/renal failure and DFU mortality, highlighting 
again the importance of addressing all risk factors as soon as people present with a 
foot ulcer.
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1 |  INTRODUCTION
Foot ulceration is a major complication of both type 1 dia-
betes and type 2 diabetes. We and others have presented evi-
dence that people with diabetes foot ulceration (DFU) have a 
higher mortality rate than diabetes alone.1- 4 This excess mor-
tality remained even after adjusting for other co- morbidities.5
A recent meta- analysis by Suluja et al. reported a 2.45 
times higher pooled relative risk of all- cause mortality in 
those with DFU compared with individuals without.6 The ex-
cess mortality was likely attributable to greater event rates of 
fatal cerebrovascular and cardiovascular disease in those with 
diabetic foot ulcers. There is a strong association between in-
creased mortality with increasing socio- economic disadvan-
tage in people with diabetes.7- 10 Wound healing however was 
largely dependent on vascular status and the characteristics 
of the foot ulcer.11
In this study, we looked at the factors linked to mortal-
ity after individuals with diabetes presented to a specialist 
Multidisciplinary Foot Clinic.
2 |  METHODS
Salford Royal NHS Foundation Trust Hospital is a large 
teaching hospital in North- West England. It is a tertiary re-
ferral centre. The hospital provides preventative foot care 
and multidisciplinary management of diabetic foot disease. 
Within Salford, the whole podiatry team is part of the multi-
disciplinary Foot Care Team (MDFC). This is an integrated 
team across primary and secondary care. Furthermore, a foot 
protection service (FPS) is provided in the community care 
setting.
Individuals with diabetes are screened for complications 
within General Practice as per NICE guidelines then risk 
stratified. Individuals classified as being at risk of foot com-
plications are referred to Salford's Foot Protection Service. 
This is a life- long service, and all patients with diabetes have 
open access to this, irrespective of their risk classification. 
We also provide a daily walk- in emergency service that pa-
tients who live in Salford or have registered with a Salford GP 
can access. Inpatients are also included in the access to our 
MDFC, in line with Putting Feet First (2016).12
People with diabetes foot problems are managed within 
the foot protection team and escalated into the MDFC clinic 
if there is an acute episode of active foot disease, such as 
‘unexplained hot red swollen foot with or without pain’, acute 
Charcot, infection not responding to treatment, osteomyelitis, 
unexplained pain or limb ischaemia. We then offer a step up, 
step down service dependent upon foot disease status at any 
one time.
All patients presenting to the Multidisciplinary Foot 
Clinic (MDFC) will have had a full holistic, neurological 
and vascular assessment, assess cardiovascular risk factors 
and offloading. We use the SINBAD ulcer classification 
system.13
Arterial Doppler studies (Huntley Digital Doppler 
[Huntleigh Healthcare Ltd, Cardiff, Wales]) and 10 g mono-
filament examination were carried out. Twenty- eight of 98 
individuals had evidence of arterial calcification. Arterial 
Brachial Index (ABI) was calculated in all patients included 
in this study.
Our MDFC consists of a Senior Diabetologist, Vascular 
Surgeon, Consultant Podiatrist, Principal Podiatrist, 
Consultant Microbiologist and Radiology consultant, sup-
ported by a diabetes specialist nurse (DSN) team who ar-
range follow- up diabetes care within the community setting.
We looked at mortality outcome for 98 individuals 
presenting consecutively to the Salford Royal Hospital 
Multidisciplinary Foot Clinic between 6 April 2016 and 26 
June 2016. Those people presenting with Charcot arthrop-
athy were excluded. Individuals were followed up for up to 
48 months. Data concerning health outcomes were extracted 
from the Salford Digital Patient (Electronic Patient) record 
(EPR). Metabolic data and BMI/blood pressure were also ex-
tracted from the Salford EPR. As many of the blood samples 
were non- fasting, we took total cholesterol as a measure of 
lipid control as this is less influenced by fasting versus non 
fasting status.
2.1 | Statistics
Data were analysed using the statistical package Intercooled 
Stata version 14.0 (StataCorp). Data are expressed as mean 
(95% CI), mean (range), or number (percentage) where rel-
evant. A multiple logistic regression analysis was used to de-
termine the association between measured risk factors and 
death. The variables included are described in the results 
Novelty statement
• We previously demonstrated in both a longitudinal 
study and in meta- analysis (pooled relative- risk 
RR, 2.45) that all- cause mortality is significantly 
higher in people with diabetes foot ulceration 
(FU) than with those without FU. In this prospec-
tive study, we looked at the factors linked to mor-
tality after presentation to podiatry with diabetes 
FU.
• We found a very high long- term mortality rate 
in individuals with DFU, greater for those with a 
hind foot ulcer and shown a close relation between 
risk of sepsis/renal failure and DFU mortality.
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section. Kaplan Meier curves were used to compare survival 
probabilities for men and women with hind foot versus fore-
foot ulceration. Chi- squared testing was undertaken to com-
pare categorical variables versus outcome (death). SINBAD 
score was compared by ANOVA.
There was no loss of individuals to follow- up.
3 |  RESULTS
3.1 | Description
Of the 98 individuals, 17 had type 1 diabetes mellitus, and 81 
had type 2 diabetes mellitus. Thirty- one were women. The 
mean age (range) was 63.6 (28– 90) years with range of dia-
betes duration 1– 45 years.
Mean duration of diabetes at presentation was 14 (95% 
confidence interval [CI] 12– 16) years. Mean HbA1c was 72 
(95% CI: 67– 77) mmol/mol. Seventy- nine individuals had an 
eGFR of <90 ml/min/1.73 m2; 48% of the people with type 2 
diabetes mellitus were treated with insulin.
Out of the group, 17 were current smokers, and 37 were 
ex- smokers; 14/98 had previously undergone an amputa-
tion. Fourteen patients had critical limb ischaemia at pre-
sentation, including one with type 1 diabetes and 13 with 
type 2 diabetes mellitus. Not all 98 people had a foot ulcer 
location that could be classified as rear foot or hind foot. 
Therefore, these individuals were excluded from the final 
analysis.
The forefoot ulcer patients were slightly older and had a 
higher body mass index (BMI) and higher eGFR with lower 
HbA1c, than the hind foot ulcer patients (Table  1). There 
was no significant difference in total cholesterol or HDL- 
cholesterol between the forefoot and hind foot groups nor in 
the % with albuminuria or in systolic/diastolic blood pres-
sure; 81% of forefoot ulcer patients were taking statins and 
83% of hind foot ulcer patients were on a statin. Anti- platelet 
agents were taken by 32% of forefoot ulcer patients and 31% 
of hind foot ulcer patients.
The characteristics of the type 1 diabetes mellitus and type 
2 diabetes mellitus patients are shown in Table 2. The type 
1 diabetes mellitus patients were younger but had a longer 
duration of diabetes than those with type 2 diabetes mellitus. 
The type 1 diabetes patients had on average a higher HbA1C, 
lower HDL cholesterol and significantly lower BMI.
3.2 | Infection rates at presentation
We used the Infectious Diseases Society of America (IDSA) 
2012 classification14 for classification of ulcer infection. 
In relation to the IDSA classification, of the 98 ulcers, 32 
were not infected, 28 were mildly infected, 24 were moder-
ately infected and 14 were severely infected at the time of 
presentation.
Osteomyelitis was present in 18/98 cases at baseline.
3.3 | Peripheral neuropathy and vascular 
insufficiency
Ninety- seven per cent of the individuals followed up had 
evidence of peripheral neuropathy on the basis of the 
International Working Group on the Diabetic Foot (IWGDF) 
monofilament guidance15 at the time of presentation; 62% of 
these studies had evidence of vascular insufficiency (Arterial 
Doppler studies) at the time of presentation; 69% of ulcers 
were forefoot in location (including toe ulcers), and 24% 
were hind foot in location (including heel ulcers). Eight per 
cent of ulcers were located above the foot; 17% of people had 
a history of previous foot ulceration.
Four of the hind foot ulcer patients and seven of the fore-
foot ulcer patients were taking an SGLT2- inhibitor, whereas 
three of each group were taking a GLP- 1 agonist (daily at the 
time of initial presentation).
3.4 | Treatment
Duration of antibiotic treatment was 12  weeks (minimum) 
for hind foot ulcers versus 6 weeks (minimum) for forefoot 
ulcers. Surgical intervention in the form of debridement at 
initial presentation was undertaken in 6% of cases of forefoot 
ulcer at presentation and in 8% of hind foot ulcers. Offloading 
measures employed included Derby sandal, total contact 
inlay, rear foot off loader, forefoot off loader and Tener boot. 
Patient concordance with offloading devices was good.
In relation to complete wound healing, 76% of patients 
achieved this over a period of up to 9 months.
There were there no differences in time to heal of osteo-
myelitis based on the location of the ulcer. Sixteen per cent 
had recurrent ulceration over the period of follow- up.
















Forefoot 64 64.6 (61.2– 68.0) 4.12 (3.87– 4.36) 1.17 (1.07– 1.26) 61.8 (56.1– 67.4) 30.9 (29.1– 32.7) 71.5 (64.9– 78.0)
Hind foot 25 60.9 (55.0– 66.8) 3.99 (3.55– 4.42) 1.25 (1.10– 1.40) 53.8 (42.9– 64.7) 28.9 (25.6– 32.1) 74.9 (65.1– 84.8)
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Nine of 98 patients required revascularization (over the 
follow- up period).
3.5 | Cause of death
Mortality rate over 4 years of follow- up was 35% for the type 
1 diabetes mellitus patients with a foot ulcer and 43% for the 
type 2 diabetes patients.
In relation to cause of death (sometimes more than one 
cause of death was listed), over the follow- up period, 40 
(40%) people died with 27% of death certificates including 
sepsis (not foot- related) as a cause— sepsis specifically in-
cluded urosepsis in 5% of the deaths. Renal failure was listed 
as cause of death in 35% of cases. Myocardial infarction/isch-
aemic heart disease was listed in 25% of cases and cancer in 
5% of cases. Pneumonia was recorded as a cause of death in 
30% of cases.
Logistic regression (stepwise backwards) analysis was 
carried out. In the regression model, we included the vari-
ables shown in Table 3. This indicated a 6.34 (95% CI: 3.92– 
8.31) fold increased risk of death with a hind foot ulcer, 
independent of eGFR (odds ratio 0.97 [0.94– 0.99]) (lower 
eGFR was associated with greater risk of death), age, BMI, 
gender, HbA1c, presence of cellulitis, presence of osteomy-
elitis, total cholesterol level, vascular insufficiency, docu-
mented neuropathy and smoking (Table 3). Smoking status 
refers to current smokers only.
The relative rate of death for hind foot versus forefoot 
ulcers is shown in Figure 1. The mortality rate was higher 
for hind foot ulcers from 6 months after initial presentation. 
We found no significant relation between the ulcer type 
(neuropathic, ischaemic or neuroischaemic) and mortality 
(χ2 = 0.12, p = 0.733). There was no difference between the 
hind foot and forefoot ulcers in SINBAD score. A higher 
SINBAD score was associated with higher mortality rate 
(F = 3.4, p = 0.01). Osteomyelitis was not specifically linked 
to mortality (χ2 = 0.35, p = 0.552).
4 |  DISCUSSION
This prospective study has indicated a very high long- term 
mortality rate in individuals with presenting to a specialist 
podiatry clinic, greater for those with a hind foot ulcer and 
shown a close relation between risk of sepsis/renal failure and 
diabetes FU mortality. This level of mortality was seen, even 






Proportion of women (%) 29.4% 32.5%
Age of diagnosis of diabetes 
(years)
27.8 ± 16.5 54.6 ± 15.2
Duration of diabetes (years) 23.2 ± 14.2 12.0 ± 7.7
Age in 2016 (years) 37.8 ± 16.5 54.6 ± 15.2
BMI (kg/m2) 23.8 ± 2.7 31.5 ± 7.4
HbA1c (mmol/mol) 81.2 ± 21.1 69.2 ± 25.6
eGFR (ml/min/1.73 m2) 53.1 ± 28.2 60.4 ± 22.6
Cholesterol (mmol/L) 4.1 ± 1.2 4.1 ± 0.9
HDL cholesterol (mmol/L) 1.4 ± 0.3 2.6 ± 11.7
Smoker % 23.5 16.3
Treated with insulin (%) 93.8 48.1
Mortality (%) 35.3 42.5
All data are presented as mean ± SD or percent unless otherwise stated.









Foot ulcer location 6.34 0.041 3.92– 8.31
Age (years) 1.06 0.061 0.99– 1.12
Gender 1.17 0.824 0.28– 4.84
Hba1c (mmol/mol) 0.99 0.488 0.95– 1.02
eGFR (ml/min/1.73 m2) 0.97 0.041 0.94– 0.99
Osteomyelitis 0.78 0.735 0.18– 3.39
Cellulitis 0.20 0.406 0.01– 8.94
BMI (kg/m2) 0.95 0.242 0.86– 1.04
Vascular 0.46 0.354 0.09– 2.37
Cholesterol (mmol/L) 1.11 0.091 0.95– 1.25
Smoking (1 = smoking) 1.22 0.082 0.92– 1.35
Neuropathy 1.05 0.103 0.92– 1.20
F I G U R E  1  Kaplan Meier survival curve for death as outcome for 
hind foot versus forefoot location of the ulcer
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though patients were attending a specialist Multidisciplinary 
Foot Clinic where a Consultant Diabetologist and Consultant 
Vascular Surgeon, Consultant Podiatrist and Consultant 
Microbiologist are in attendance. This again highlights the 
importance of addressing all risk factors as soon as people 
present with a foot ulcer. Furthermore, risk of death was 6.3 
times higher in people with a hind foot ulcer.
The presence of urosepsis as a contributory cause of death 
in many cases may relate to the fact that foot ulceration often 
occurs in people with suboptimal glycaemic control which 
itself can lead to impaired neutrophil function16 and conse-
quently to a greater likelihood of a urinary tract infection 
progressing to full blown urosepsis. This also relates to pneu-
monia being recorded as a cause of death in 30% of cases.
The increased mortality rate associated with hind foot 
versus forefoot ulcers highlights the more serious nature of 
ulcers at that location likely associated with poorer tissue 
perfusion in patients with such an ulcer location. Also, hind 
foot ulcer is a marker of poorer overall health with reduced 
mobility being a consequence of that poorer overall health. 
This accords with the findings of the National Diabetes Foot 
Care Audit17 which indicated more adverse outcomes in term 
of amputation and death when a hind foot ulcer is present. 
The association of a higher SINBAD score with increased 
mortality accords with the findings of the National Diabetes 
Food Audit.17
It has been demonstrated that 5- year mortality for dia-
betes with foot ulceration is around 40%.18,19 The results 
of our study (just under 4 years follow- up) are of a similar 
order of magnitude to this. It is likely that higher mortality 
rates observed occur as a result of cardiovascular and non- 
cardiovascular complications of diabetes such as sepsis20 as 
we have found here. A study by Young et al. showed that an 
aggressive program of cardiovascular risk management can 
reduce mortality rates to as low as 26% in individuals with 
diabetic foot ulceration.21
Previous studies have shown increased mortality asso-
ciated with heel ulcers. In the European Study Group on 
Diabetes and the Lower Extremity (EURODIALE) study, 
ulcer location had a significant effect on the outcome. Both 
time to healing and mortality was highest in individuals with 
heel ulcers. Compared with those with mid- foot and forefoot 
ulcers.22 Also, significantly more people with heel ulcers are 
unable to stand or walk without help compared with those 
with forefoot and mid foot ulcers. Such immobility, as well 
as being associated with the ulcer itself, is probably related to 
co- morbidities including renal failure, of which there was a 
trend in the heel ulcer group. Location of foot ulcer is known 
to contribute to poor physical functioning.22,23
In relation to infrapopliteal arterial disease, in a further 
study, those people with an ischaemic heel ulcer were at in-
creased risk of mortality compared with those with a forefoot 
ulcer. One- year and 3- year amputation free survival was 66% 
and 44% for forefoot wounds and respectively 48% and 21% 
for heel wounds.24,25
Our results accord with the findings of the National 
Diabetes Foot Care Audit and the prospective study of 
Jeyaraman et al5,14 both of which indicated more adverse out-
comes in terms of amputation and death when a hind foot 
ulcer is present. Overall, patients with hind foot ulcers suffer 
from diminished general health and prolonged immobility 
and die from their co- morbidities, including renal failure and 
cardiovascular disease. A summary of recent studies describ-
ing mortality rates in people with diabetes foot ulceration is 
given in a recently published meta- analysis.6
The occurrence of a diabetes foot ulcer has a marked im-
pact on the person's activity level, and when combined with 
slow resolution, the condition is understandably linked with 
a reduction in quality of life.26 With regard to the incidence 
of depression, reports are mixed. One group reported that 
incident first ulcers are associated with depression and that 
this is independently associated with mortality at 5 years.27 
However, other investigators have reported that both quality 
of life and depressive symptoms are reversed by healing— 
either with or without amputation.28,29
The findings of our study suggest that in people with di-
abetes, hind foot ulcers must be seen as a harbinger of more 
adverse outcomes than foot ulcers at other sites, with tight 
control of glycaemia and focused management of cardiovas-
cular and renal parameters being a priority, in addition to 
regular specialist podiatry input. We believe that the findings 
here can be generalised to other parts of the United Kingdom 
and beyond, because of the broad demographic range of our 
patient group, coming as they do from all over the Greater 
Manchester conurbation.
4.1 | Limitations/Strengths of our study
Our dataset is limited by the number of patients who pre-
sented in the recruitment time frame at a single centre. 
Another limitation of the study is the relatively small num-
bers compared with previously done prospective studies in 
this regard, though the relatively robust and long duration 
of follow- up somewhat offsets this limitation. Screening for 
signs of autonomic neuropathy (given its association with in-
creased mortality rate)30 would have provided an additional 
relevant variable for the multiple regression analysis. We ac-
cept that this is the limitation of the study, and further work in 
this area will include tests for autonomic neuropathy.
A further limitation is the lack of a control population 
of diabetes without foot ulcers. Nevertheless, this is a pro-
spective evaluation of outcome using data available from the 
Salford EPR, and follow- up was for a period of up to 4 years.
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5 |  CONCLUSION
This prospective study has indicated a very high long- term 
mortality rate in individuals with DFU, greater for those with 
a hind foot ulcer and shown a close relation between risk of 
sepsis/renal failure and DFU mortality.
This again highlights the importance of addressing all risk 
factors as soon as people present with DFU to their family 
doctor or specialist service. All measures must be taken to 
achieve and sustain good glycaemic control following pre-
sentation with a diabetes foot ulcer.
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